Skip to main content
Innate Pharma logo

Innate Pharma — Investor Relations & Filings

Ticker · IPH ISIN · FR0010331421 LEI · 9695002Y8420ZB8HJE29 PA Manufacturing
Open in API
Filings indexed 1,403 across all filing types
Latest filing 2024-05-15 Regulatory Filings
Country FR France
Listing PA IPH

About Innate Pharma

http://www.innate-pharma.com/

Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated May 15, 2024, announcing that four abstracts related to Innate Pharma's drug candidates (SAR443579 and IPH6501) have been accepted for presentation at the European Association of Hematology (EHA) 2024 Congress. This type of announcement, detailing scientific data presentation schedules and providing context on ongoing research and collaborations, is characteristic of an announcement intended to inform investors and the public about scientific progress, often preceding a formal earnings release or a dedicated investor presentation. Since it is a press release announcing scientific updates and progress rather than a full financial report (10-K, IR), a management discussion (MDA), or a formal proxy/voting document, it fits best under the general category of Investor Relations communication. Given the options, it is a specific type of corporate communication that is not explicitly covered by the more specific codes like ER, IP, or CT. However, it is a formal announcement of corporate/scientific progress. Since it is not a full report, and it is not a management change (MANG) or director dealing (DIRS), it is most appropriately classified as a general Regulatory Filing (RNS) as a catch-all for important, non-standard announcements, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of accepted abstracts. Given the nature of providing scientific highlights and updates, and lacking a better fit among the specific codes, RNS (Regulatory Filings/General Announcement) is the most suitable fallback, although it strongly resembles an Investor Presentation announcement. Since it is a press release format announcing scientific data acceptance, and not a formal financial report, RNS is the safest classification based on the provided definitions, as it is a general regulatory/corporate announcement.
2024-05-15 English
Informations privilégiées / Autres communiqués
Investor Presentation Classification · 1% confidence The document is a press release dated May 15, 2024, announcing that four abstracts related to the company's drug candidates (SAR443579 and IPH6501) have been selected for presentation at the upcoming EHA (European Hematology Association) congress in June 2024. It details the titles and types of abstracts (Oral Presentation, Poster) and includes standard corporate boilerplate, forward-looking statements, and contact information. This type of announcement, which publicizes scientific data to be presented at a medical conference, is typically classified as an Investor Presentation (IP) if it were the presentation itself, or an Earnings Release (ER) if it were summarizing financial results. Since this is an announcement about scientific data presentation and clinical trial updates, and not a formal financial report (like 10-K or IR) or a general regulatory filing (RNS), the most appropriate category is Investor Presentation (IP), as these announcements often serve to update investors on R&D progress and pipeline milestones, which is a key component of investor relations materials. It is not a short announcement merely pointing to an attached report (RPA/RNS).
2024-05-15 French
6-K
Foreign Filer Report
2024-05-14 English
Quarterly financial reporting / First quarter financial report
Earnings Release Classification · 1% confidence The document is explicitly titled "INNATE PHARMA REPORTS FIRST QUARTER 2024 BUSINESS UPDATE AND FINANCIAL RESULTS" and contains detailed financial figures for the quarter ending March 31, 2024, including cash position (€113.9 million) and revenues (€6.6 million). It also includes extensive pipeline updates and mentions a conference call scheduled for the same day. This structure—a summary of recent operational and financial performance for a specific interim period (Q1 2024)—is characteristic of an Interim/Quarterly Report (IR). It is not the full Annual Report (10-K), nor is it merely an announcement of a report (RPA), as it contains the core results and updates directly. It is more comprehensive than a simple Earnings Release (ER) which usually contains only key highlights. Q1 2024
2024-05-14 English
Information financière trimestrielle / Information financière du premier trimestre
Earnings Release Classification · 1% confidence The document is titled "INNATE PHARMA FAIT LE POINT SUR SES ACTIVITES ET PUBLIE SES RESULTATS FINANCIERS POUR LE PREMIER TRIMESTRE 2024" (Innate Pharma provides an update on its activities and publishes its financial results for the first quarter of 2024). It explicitly mentions key financial figures for the first three months of 2024 (Q1 2024), such as revenue (€6.6 million) and cash position (€113.9 million as of March 31, 2024). It also announces a conference call to discuss these results. This content structure—a summary of operational and financial highlights for a specific interim period, followed by details on pipeline progress and a call announcement—is characteristic of an Earnings Release (ER). It is not the full, comprehensive report (which would be an IR or 10-K), nor is it just a notice of publication (RPA). Q1 2024
2024-05-14 French
6-K
Foreign Filer Report
2024-05-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.